MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
By A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli and 4 more. Journal of Clinical Oncology, 2008
796 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/ea59004b25c5c76af2dd7a88d99acd28dfebd4e7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Michael Weller
- R. Stupp
- Guo-li Ming
- Guido Reifenberger
- Hongjun Song
- Kenneth D. Aldape
- P. Wen
- D. Reardon
Citations in the corpus
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “However, MGMT methylation status may be useful in these patients to distinguish pseudoprogression (PsPD) from true progression [16].”
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. (2019, background): “Another patient (UP-7884), with reduced KI67+ cells in GBOs from 2 subregions, had no recurrence in the temporal region and exhibited a pattern favoring pseudo-progression in the frontal region (Figure S6B), which has been associated with extended survival (Brandes et al., 2008; Roldán et al., 2009)”
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “completion of radiotherapy with concomitant chemotherapy, and may be more common in patients with MGMT-methylated tumors, possibly signifying the extent of cytotoxic effects of treatment.(65) Some have speculated that the increase in overall survival observed in patients”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “An incidence of >60% pseudo-progression has been reported among patients with early radiological progression after radiochemotherapy [66].”
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “This phenomenon, termed pseudoprogression, likely results from transiently increased permeability of the tumor vasculature from irradiation, which may be enhanced by temozolomide, and complicates the determination of tumor progression immediately after completion of radiotherapy.(26-30) Pseudoprogre”